# Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

> **NCT01933906** · PHASE1 · COMPLETED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 12 (actual)

## Conditions studied

- Chronic Phase Chronic Myeloid Leukemia

## Interventions

- **DRUG:** P1101

## Key facts

- **NCT ID:** NCT01933906
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-30
- **Primary completion:** 2018-11-14
- **Final completion:** 2018-11-14
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01933906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01933906, "Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01933906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*